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Abstract: Despite efforts to decrease tobacco use, smoking continues to be a leading cause 
of preventable morbidity and premature death. The associated economic burden is substantial, 
both in the form of direct costs (healthcare expenditures) and indirect costs (lost productivity), 
regardless of whether the burden is assessed from the standpoint of an employer, a health 
plan, or society as a whole. Cessation programs are considered among the most cost-effective 
in healthcare, and are often used as a benchmark for other medical interventions. This analysis 
specifically considers the cost-effectiveness of varenicline, a novel α4β2 partial agonist used 
for smoking cessation, in comparison to other approved therapies. Clinical trial data have 
demonstrated that varenicline has the ability to decrease cravings and withdrawal symptoms, 
and lessen positive reinforcement associated with smoking. Varenicline’s novel mechanism 
has translated into superior efficacy in comparison to other available therapies. For this reason, 
despite an initial cost that typically exceeds that of other medications, varenicline is a cost-
effective option for smoking cessation.
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According to the World Health Organization, more than one billion persons worldwide 
routinely smoke, and despite efforts to aid people in their attempts to quit and the 
provision of education about the dangers of tobacco use, it is estimated that the number of 
people who smoke will climb to more than 1.6 billion by the year 2025.1 The economic 
burden associated with smoking affects all of society, and though the perspective from 
which the burden is analyzed alters the impact, the costs remain substantial. Direct 
medical costs, which include such things as medications, medical services (both 
inpatient and outpatient), institutional care, diagnostics, and ER visits, were estimated 
to be greater than US$75.5 billion in 1998, while indirect costs, such as lost wages and 
decreased job performance, contributed another US$92 billion.2 Individuals who smoke 
consume 40% more health care costs than nonsmokers.3 Tobacco use is the leading 
cause of preventable illness and premature death.4
Treatment options for smoking cessation
Because it is well documented that quit attempts are substantially more successful when 
pharmacotherapy is employed, experts advise that medications be used unless there is a 
specific contraindication for doing so.5 Medications approved by the US Food and Drug 
Administration (FDA) for use in the treatment of nicotine dependence include various ClinicoEconomics and Outcomes Research 2009:1 26
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nicotine replacement therapies (NRT) including patches, 
lozenges, inhalers, nasal spray and gum, the antidepressant 
bupropion, and varenicline (Chantix®; Pfizer, New York, 
USA). Other medications sometimes used for smoking 
cessation therapy include clonidine and nortriptyline, though 
neither is FDA approved for this purpose.
Nicotine replacement works by acting on the same 
nicotinic receptors in the central nervous system (CNS) that are 
stimulated when cigarette smoke is inhaled. Nicotine binding 
to these receptors results in the release of dopamine and nor-
epinephrine. Stimulation of dopamine receptors in particular is 
believed to be responsible for the properties of tobacco smoke 
that ultimately lead to addiction.6 The acetylcholine receptors 
on dopaminergic neurons in the mesolimbic system in the brain 
are known to play a role in pleasure and reinforcement. Because 
nicotine exerts its effects on the receptor for a prolonged time 
period, upregulation occurs. This leads to desensitization of 
the receptor, and results in physical dependence, tolerance, and 
ultimately to symptoms of withdrawal should the smoker quit 
without an aid to offset these effects.7 NRT is used primarily to 
decrease symptoms of withdrawal while the smoker is gradually 
weaned from the physical addiction. Unlike the inhalation of 
nicotine contained in smoke, which allows for nearly immedi-
ate effects on receptors and virtually instant satisfaction for the 
smoker, replacement therapies have a slower onset, allowing the 
user to become less accustomed to immediate reinforcement.8 
By decreasing withdrawal symptoms, replacement therapy 
allows the smoker to focus on necessary changes in behavior. 
NRT has been shown in clinical trials to increase quit rates by 
up to twice that noted in smokers who attempt to quit without 
pharmacologic therapy.5 In general, trials have not demon-
strated a substantial difference in efficacy among the various 
available dosage forms, and thus the decision about which one 
to use is up to the smoker and the prescriber.4
Bupropion is also used in an oral sustained-release (SR) 
formulation as an aid to smoking cessation. It was the first 
non-nicotine medication to be FDA approved for this purpose. 
Previously, the drug had been marketed as an antidepressant 
medication (Wellbutrin®; GlaxoSmithKline, North Carolina, 
USA). Bupropion is now available in a generic formulation. 
The drug is a weak inhibitor of dopamine and norepineph-
rine uptake, and may have some ability to cause the release 
of dopamine and inhibit nicotinic receptors.4,9 Clinical trials 
have demonstrated the ability of bupropion to approximately 
double the successful quit rate compared to no therapy.5
In 2008, the US Department of Health and Human 
Services put forth revised clinical practice guidelines 
for treating the use of and dependence on tobacco.5 The 
guidelines place both nicotine replacement and bupropion 
in the category reserved for first-line agents based on their 
safety profiles and the amount of robust trial data available 
for both. Clonidine (despite having level A strength of 
evidence for efficacy and clinical trial data which suggest 
its use can double quit rates) was classified as a second-line 
agent due to lack of FDA approval, its side-effect profile, and 
the need for a specific dosing regimen for use in smoking 
cessation. Similarly, nortriptyline was classified as second 
line, again due to lack of FDA approval, its side-effect profile, 
and a limited number of clinical studies with small sample 
sizes (strength of evidence = level B).5 Varenicline was not 
included, presumably because it was still a relatively new 
agent at the time the guidelines were being formulated.
A novel oral medication for the treatment of nicotine 
addiction, varenicline received FDA approval in May 2006. 
The drug is a derivative of cytisine, a substance found to be 
useful in controlling cravings for nicotine when the leaves of 
the golden rain tree (Koelreuteria paniculata) were substituted 
for tobacco during World War II.6 In fact, cytisine is used in 
Eastern Europe as an aid for smoking cessation. Structurally, 
varenicline is similar to nicotine. The drug is a partial agonist 
at the α4β2 nicotinic receptor. Through its partial binding, it 
mimics the effects of nicotine, though the reinforcing effects of 
varenicline are less. Its nicotinic receptor binding also results in 
the release of dopamine and a decrease in cravings. By prevent-
ing receptor access to nicotine, varenicline is able to block the 
expected reinforcing effects.4 Typically, the drug is given at 
a dose of 0.5 mg daily for the first 3 days, 0.5 mg twice daily 
for the next 4 days, and then on the eighth day (generally the 
scheduled quite date), the drug is titrated up to its final dose 
of 1 mg twice daily. Because the recommended schedule to 
set a quit date is 8 days after initiation of therapy, it has been 
hypothesized that positive reinforcement may actually decrease 
with each cigarette smoked during the lead-in week.10
Efficacy of varenicline
Study data have shown varenicline to be superior to placebo 
for smoking cessation.11,12 In addition, multiple trials have 
demonstrated varenicline to be efficacious when compared 
to other active treatments. Though an exhaustive review 
of efficacy trials is beyond the scope of this publication, 
available data from trials comparing varenicline to other 
medication approved for smoking cessation are summarized 
below (Table 1).
A phase II trial by Nides et al was designed to compare 
three different doses of varenicline to bupropion and 
placebo.13 Six hundred thirty-eight subjects were enrolled and ClinicoEconomics and Outcomes Research 2009:1 27
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randomized to receive varenicline (0.3 mg daily, 1 mg daily, 
or 1 mg twice daily), bupropion SR 150 mg twice daily or 
matched placebo. Enrollees in each arm also received brief 
counseling (approximately 10 minutes) on a weekly basis. 
Treatment was ongoing for 7 weeks. Study subjects had to 
have smoked an average of 10 cigarettes daily for the previ-
ous year. Abstinence was confirmed by carbon monoxide 
level evaluation. At 4 weeks, the continuous quit rate (CQR, 
defined as continuous abstinence from smoking), was 48% 
for the varenicline 1 mg twice daily group, and 37.3% for 
the 1 mg daily group (P  0.001 vs placebo for both). In 
comparison, the bupropion CQR was 33.3% (P  0.002 vs 
placebo). The 4-week CQR was thus essentially tripled for 
the 1 mg twice daily dose of varenicline and doubled for the 
bupropion SR arm (both vs placebo (17.1%)). An optional 
nondrug treatment phase was continued through week 52, and 
the results for continued abstinence after week 4 to the end 
of the study favored varenicline 1 mg twice daily (14.4%) 
compared with placebo (4.9%, P = 0.002). Bupropion users 
did not maintain a statistically significant CQR vs placebo 
at week 52 (6.3%, P = 0.6).
Aubin and colleagues conducted a phase III trial of 
varenicline compared with transdermal nicotine.14 The trial 
was of open label design, and 746 subjects were enrolled. The 
regular varenicline titration schedule was followed and the 
drug was given for 12 weeks. The nicotine patch was dosed 
at 21 mg/day for 6 weeks, and then 14 mg/day and 7 mg/day, 
each for 2 weeks (total therapy duration for transdermal 
nicotine was 10 weeks). Subjects using nicotine replacement 
stopped smoking the day treatment was initiated. Follow up 
continued to week 52. The carbon monoxide-confirmed CQR 
for weeks 9 for 12 significantly favored varenicline (55.9% 
vs 43.2% for nicotine, P  0.001). The CQR at week 52 did 
not reach statistical significance, but still favored varenicline 
(26.1% vs 20.3% vs nicotine, P = 0.056). Potentially, the open 
label design of the study and the difference in total treatment 
time (2 additional weeks for varenicline) had some effect on 
the study outcomes.
Two additional phase III trials of identical design were 
completed to compare varenicline therapy to bupropion SR 
and placebo.15,16 Smokers in both studies were randomized to 
receive one of the three therapies in addition to brief weekly 
counseling. All subjects were followed for 52 weeks, 12 of 
which consisted of drug therapy (or placebo). The number 
of subjects enrolled in the two studies was nearly identical at 
102515 and 1027.16 The standard varenicline titration schedule 
was followed. Bupropion SR was administered at a dose of 
150 mg daily for the first 3 days, and was then titrated to 150 mg 
twice daily for the remainder of the active treatment phase. The 
primary outcome was carbon monoxide-confirmed CQR from 
weeks 9 to 12. Subjects in the first study15 that were randomized 
to varenicline achieved abstinence at a rate of 44% vs 17.7% 
for placebo (P  0.001). Results from the second study16 
were similar (varenicline CQR 43.9% vs 17.6% for placebo, 
P  0.001). Additionally, CQR was significantly higher 
vs bupropion SR for both studies (29.5%, P  0.00115 and 
29.8%, P  0.001.16) Of note, the CQR for weeks 9 to 12 was 
significant for bupropion SR compared to placebo (P  0.001, 
both studies) as well. The first of the secondary endpoints, CQR 
at weeks 9 to 24, demonstrated significance for varenicline 
compared with placebo for both study groups (29.5% vs 10.5%, 
P  0.00115 and 29.7% vs 13.2%, P  0.001.16) Varenicline 
remained significantly more effective than bupropion at this 
time point as well. The final outcome measure, CQR at weeks 
9–52 again demonstrated superiority for varenicline vs placebo 
(21.9% vs 8.4%, P  0.00115 and 23% vs 10.3%, P  0.00116). 
However, the CQR for bupropion in the first study (16.1%) 
was not significantly different from varenicline (P = 0.057).15 
Varenicline maintained superiority in the second study with 
bupropion users achieving a CQR of 14.6% (P = 0.004).16
Table 1 Fifty-two week continuous abstinence rates with varenicline versus bupropion SR or nicotine replacement
Study Design Treatment groups Abstinence at 52 weeks P value
Nides et al13 R, DB, PC 
n = 638
varenicline 1 mg bid (7 weeks) 
bupropion SR 150 mg bid (7 weeks)
14.4%  
6.3%
0.01
Gonzales et al15 R, DB, PC 
n = 1025
varenicline 1 mg bid (12 weeks) 
bupropion SR 150 mg bid (12 weeks)
21.9%  
16.1%
0.057
Jorenby et al16 R, DB, PC 
n = 1027
varenicline 1 mg bid (12 weeks) 
bupropion SR 150 mg bid (12 weeks)
23%  
14.6%
0.001
Aubin et al14 R, OL 
n = 746
varenicline 1 mg bid (12 weeks) 
TN 21 mg/day (6 weeks), 14 mg/day 
(2 weeks), 7 mg/day (2 weeks)
26.1%  
20.3%
0.056
Abbreviations: R, randomized; DB, double-blind; PC, placebo-controlled; OL, open label;   TN, transdermal nicotine.ClinicoEconomics and Outcomes Research 2009:1 28
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In addition to the studies above which were designed to 
evaluate varenicline efficacy, a novel study has been conducted 
to determine if varenicline could be used to maintain absti-
nence beyond the standard treatment duration. Varenicline was 
initially given for the typical 12 weeks of therapy achieving a 
CQR of 64.1% (n = 1210).10 (This CQR is substantially higher 
compared to those in other studies with varenicline, likely 
due to the open label design of the first part of the study). The 
subjects were subsequently randomized to receive varenicline 
or placebo for an additional12 weeks to determine if continued 
maintenance therapy resulted in better long-term outcomes. 
Subjects were followed for 52 weeks. CQR from weeks 13 
to 24 was 70.5% for varenicline compared with 49.6% for 
placebo (P  0.001). Varenicline superiority was maintained 
at 52 weeks with 43.6% of subjects achieving continued 
abstinence vs 36.9% of placebo users (P = 0.02). This study 
demonstrated that prolonged use of varenicline has the poten-
tial to result in higher CQR over time. In fact, varenicline is the 
first medication to demonstrate the ability to prevent relapse 
prevention in a significant manner.
Cost-effectiveness
An analysis of the cost-effectiveness of a particular therapy 
is accomplished by comparing that therapy to alternative 
interventions with regard to definitive common outcomes 
such as life-years saved (LYS), quality adjusted life-years 
(QALY) gained (a measure that takes into account years that 
are affected by illness and adjusts their value accordingly in 
comparison to years of good health), or cases of illness or dis-
ease prevented.18 It is known that smokers who quit decrease 
their risk of coronary heart disease by 50% within a year, and 
that sustaining non-smoking status for 15 years brings the risk 
equal to that of someone who never smoked.19 Similarly, the 
risk of stroke and lung cancer declines substantially within a 
decade. The resources saved by decreasing smoking-related 
morbidity add significantly to the cost-effectiveness of an 
intervention. In fact, smoking cessation is among the most 
cost-effective health care interventions, and is considered a 
criterion standard.20,21 There is no universally accepted thresh-
old for cost-effectiveness, but a cost per QALY gained under 
US$50,000 is generally considered positive.22 Cessation 
programs consistently achieve results substantially below 
this dollar amount. There are a number of cost-effectiveness 
analyses for smoking cessation therapies, but to date only a 
small number have included varenicline (Table 2).
A cost-benefit analysis of varenicline compared with 
bupropion was conducted from the perspective of an employer 
as payer.23 Outcomes data from a previously published 
study were utilized in the analysis.15 A decision tree model 
was utilized to determine the net benefit of therapy over a 
12-month time period. The costs were standardized to 2006 
dollars. A discount rate, often included in cost-effectiveness 
analyses that cover an extended time horizon since a given 
amount of money will be worth more today than in the future, 
was not done due to the 12-month limitation. Patient counsel-
ing was set at US$20 per visit, and each visit to the prescriber 
was set at US$51 using current procedural terminology (CPT) 
codes. Treatment costs corresponding to each therapy were 
US$639.80 (varenicline), US$598 (generic bupropion SR), 
US$717 (brand name bupropion SR), and US$371 (placebo), 
each administered for 12 weeks. A 12-month cost savings of 
US$5,390 per nonsmoking employee was determined using 
data previously published, though the estimated cost was 
modified by the investigators due to the exclusion of morbid-
ity and mortality (again due to the short period of analysis), 
property damage and maintenance estimates, and involuntary 
smoking (since most workplaces were now smoke-free).24 
Varenicline was considered most beneficial in terms of yearly 
cost savings to the employer (US$540.60 per nonsmoker), the 
next most beneficial intervention being generic bupropion SR 
(US$269.80 per nonsmoker). A sensitivity analysis (modi-
fication of estimated study values to determine if outcomes 
will be consistent if they are higher or lower than those used 
in the original analysis) was conducted by the investigators. 
Twelve-month savings per quitter was varied from US$500 
to US$6,000. The threshold where varenicline was the most 
cost-beneficial was US$1,184. Quit rates (QR) for each 
treatment group were also varied, and it was determined that 
the QR for varenicline would have to be less than 17% for 
bupropion SR to become more cost-effective (an unlikely 
scenario given the quit rates reported in the efficacy studies 
summarized previously). Twelve-week treatment cost vari-
ance demonstrated that the cost of varenicline would have 
to increase to US$616 per quitter for the drug to lose its 
advantage over the other therapies.
A second study conducted from the perspective of the 
Dutch healthcare system estimated the cost per QALY gained 
and savings in direct costs from a single cessation attempt.25 
A BENESCO (Benefits of Smoking Cessation on Outcomes) 
model was used to simulate the consequences of tobacco use 
and the benefits of quitting (including medication costs and 
decrease in morbidity and mortality). A hypothetical subject 
cohort of 884,000 was followed until all had died. Treatment 
groups included those who used varenicline, bupropion SR, 
NRT (dosage form not specified), nortriptyline or no medica-
tion therapy. Four disease states commonly associated with ClinicoEconomics and Outcomes Research 2009:1 29
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smoking, COPD, lung cancer, coronary heart disease and 
stroke, were included in estimates of morbidity and mortality. 
In addition, severe asthma exacerbation was modeled. 
Though it is certainly possible for a single individual to 
have more than one of these diseases simultaneously, for 
the purposes of the study each was mutually exclusive with 
any subject assumed to have only one at a time. Costs were 
adjusted to 2004 values, and future costs were discounted 
at a rate of 4%. In the base model, one in four smokers 
was expected to make a quit attempt. In terms of number 
of diseases avoided, varenicline was most favorable. The 
model allowed for 28,000 incidents avoided in varenicline 
users, 58% of those being cases of COPD. Compared with 
unaided cessation, varenicline cost was €320 per QALY 
gained. This was substantially less than bupropion (€990) and 
NRT (€1,720). In comparison, nortriptyline was cost-saving. 
Varenicline cost alone (per additional quitter) was higher 
compared with bupropion and NRT (€1,350 and €1,030 
respectively); however, because of superiority in efficacy, the 
drug remained cost-saving. Compared with nortriptyline, the 
cost of varenicline per additional quitter was €4,270, with an 
additional €1,650 spent per QALY gained. Despite this higher 
cost, the price paid per QALY gained with varenicline is still 
far below the cost-effectiveness threshold previously defined. 
A sensitivity analysis revealed that increasing the cost per 
QALY gained to €5,000 and varying other components of the 
model would produce results that maintained varenicline as 
the most cost-effective option more than 80% of the time vs 
bupropion SR, NRT, and no drug therapy, and greater than 
60% of the time vs nortriptyline. Of note, the results of the 
study are believed to be conservative since a limited number 
of diseases recognized as associated with smoking were 
included, and because the model did not include exposure 
of nonusers to tobacco smoke.
Another hypothetical cohort of subjects was followed for 
10 years to evaluate the impact of varenicline, brand-name 
bupropion SR, NRT (patches), or no medication use on 
private health plans, Medicaid plans, and employer (work-
place) cost.26 Forty-three percent of subjects were expected 
to make an attempt at quitting each year. Cessation rates 
and intervention data were taken from previous studies. The 
group that was not given drug therapy received intervention 
in the form of short 10-minute counseling sessions (estimated 
cost/session = US$73.04). Both varenicline and bupropion SR 
were administered for 12 weeks, whereas NRT was given for 
9 weeks. Relapse rates were modeled after the 1990 Surgeon 
General’s report on Smoking and Health.27 A discount rate 
of 3% per year was employed. Based on the model used, an 
additional 14% of subjects successfully quit smoking using 
varenicline compared to bupropion SR. When compared 
to NRT and no drug therapy, quit rates with varenicline 
were 25% and 38% greater, respectively. Eventual cases 
of coronary heart disease were estimated to be fewer with 
varenicline than with other treatments (three, six and nine 
fewer cases compared to bupropion SR, NRT and no drug 
therapy respectively). COPD data were similar. Overall, the 
total cohort cost for varenicline was US$10,000 less than for 
bupropion SR. For the other therapies, the cost of varenicline 
was initially greater (US$42,000 vs NRT and US$115,000 vs 
no drug therapy). However, 2 years into the model, the savings 
in healthcare costs were higher for varenicline compared with 
both NRT (US$35,000) and no drug therapy (US$54,000) 
owing to the increase in successful quit attempts. For work-
place savings (avoidance of absenteeism and lost productivity 
estimated at 1.59 work days/year per smoker28), the estimated 
return on investment (ROI) as decreased costs of healthcare 
was US$2.60 for each US$1 spent on varenicline instead 
of NRT at 5 years, and US$6.70 at 10 years. Considering 
both healthcare costs and workplace costs, the internal rate 
of return (IRR) was US$16.90 at 5 years, and US$34.00 at 
10 years for those given varenicline. When all other inter-
ventions were considered and both the costs of healthcare 
and workplace costs were taken into account, the IRR was 
consistently positive and the ROI was always  US$1 within 
the first year for varenicline users. Varenicline proved to be 
cost saving immediately compared to bupropion SR, and was 
cost saving within five years for NRT and no drug therapy. 
Regardless of the payer considered, costs of smoking cessa-
tion with varenicline and associated healthcare costs were 
lower versus bupropion SR. A comparison of varenicline to 
no drug therapy resulted in the former being cost-effective at 
2 years for both the private health plan model (US$648 per 
quit) and the Medicaid model (US$836 per quit). Healthcare 
and workplace cost savings with varenicline per 1000 model 
cohorts was US$575,000 vs bupropion SR, US$1,106,081 vs 
NRT, and US$1,686,203 vs no drug therapy at 10 years.
A study conducted from the perspective of the Swedish 
economy compared the cost-effectiveness of varenicline and 
bupropion SR.29 A BENESCO model that included indirect 
costs was used. Monetary values were adjusted to 2003, 
and a discount rate of 3% was employed. In the base model, 
one in four subjects was assumed to attempt to quit smok-
ing, and success rates for varenicline and bupropion (22.5% 
and 15.7% respectively) were modeled.15,16 Varenicline was 
administered for 12 weeks at a cost (including visits to a 
general practitioner an motivational support visits) of €452 ClinicoEconomics and Outcomes Research 2009:1 31
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per subject, and bupropion SR was given for 7 weeks at a cost 
of €419. Bupropion users were also provided two additional 
motivational support visits compared to the varenicline group. 
Taking both direct and indirect costs into consideration, for each 
female member of the cohort an additional €1,193 was spent per 
QALY gained at 20 years when varenicline was used instead 
of bupropion. For males, the cost was €2,056. At 50 years, 
costs for the varenicline group were €14,214 and €14,743 for 
females and males respectively. Considering only direct costs 
(ie, costs of healthcare only), varenicline cost per QALY gained 
was €3,852 less at 20 years and €3,115 less at 50 years for 
females. Varenicline use saved €2,987 at 20 years and €2,340 
at 50 years for male cohort members. Therefore, when taking 
only direct costs into account, varenicline was cost saving, and 
the cost-effectiveness ratio was positive when the net costs of 
increased survival due to saved morbidity-related costs were 
considered. There were an estimated 9,200 LYS per 100,000 
smokers when varenicline was used instead of bupropion. This 
number equates to approximately 500 per 100,000 members 
of the general population. A sensitivity analysis resulted in 
no change to the overall study conclusions. When varenicline 
efficacy was decreased to 19% and cost increased to €2,000, 
the maximum cost per QALY gained was achieved (€42,503 
for females at 20 years). The investigators noted that there is 
currently no consensus among decision makers on whether to 
include or exclude future effects on consumption and produc-
tion (indirect costs).
Another cost-utility analysis utilizing a BENESCO model 
was conducted to compare varenicline, bupropion SR, NRT 
(the cost of which was determined by calculating a weighted 
average cost for all NRT formulations based on International 
Medical Statistics prescribing data), and no treatment (not con-
sidered to be associated with any cost).30 Costs were adjusted 
to 2005 US dollars, and a discount rate of 3% per year was 
applied. The study was conducted from the perspective of 
the US healthcare system, and only direct costs were taken 
into account. Per-subject treatment costs were US$370.96 for 
varenicline, US$264.40 for bupropion SR, and US$405.47 for 
NRT, each administered for 12 weeks. The assumption used in 
the base case scenario was that 25% of the smoking population 
would attempt a quit in the first year of the model (the only quit 
attempt considered in the analysis). The cohort (n = 11,925,455) 
was followed for a lifetime horizon. Rates of efficacy were 
taken from published trials.15,16 For the lifetime of the cohort, 
the incremental cost per QALY gained for varenicline was 
US$1,884, a value dominant over all other treatments. When 
a scenario analysis that assumed zero cost for bupropion and 
for NRT was conducted, the cost-effectiveness of varenicline 
remained with an additional US$1,968 and US$1,901 spent 
per QALY gained vs bupropion and NRT respectively. The 
incremental cost per QALY gained was consistently less than 
US$30,000 when 1,000 simulations were run during a proba-
bilistic sensitivity analysis 77.3% of the time for varenicline 
versus bupropion, 83.6% of the time vs NRT, and 82.5% of 
the time vs no treatment. Varenicline use was estimated to 
prevent 143,965 deaths over the lifetime of the model from 
smoking-related disease (including COPD, coronary heart 
disease, lung cancer, and stroke), thereby saving additional 
resources compared to the other treatment options. As in 
previous models, owing to its superior efficacy as a smoking 
cessation aid, varenicline resulted in lower expenditures for all 
direct medical costs (cost of morbidity from disease and cost of 
cessation therapy). Varenicline costs for the cohort (lifetime) 
were US$2,416 million less than bupropion, US$4,119 million 
less than NRT and US$4,741 million less than no treatment.
The final study providing cost-effectiveness data for 
varenicline was actually conducted to determine the utility 
of employing pharmacogenetic testing to help choose the 
best approach to smoking cessation treatment in a given 
individual.31 The model compared varenicline, bupropion SR, 
NRT (patch), and genetic testing (to choose between bupropion 
and NRT). Forty-thousand hypothetical smokers were included 
in the analysis (a Monte Carlo simulation). A sensitivity analy-
sis was completed, and a discount rate of 3% annually was 
applied to the base case. Therapy models were NRT for eight 
weeks, bupropion for ten weeks, and varenicline for 12 weeks, 
each with minimal counseling. Incremental cost-effectiveness 
ratios (ICER) were determined to estimate LYS. The ICER of 
varenicline in the base case scenario was US$2,985 per LYS 
(vs bupropion) compared to US$1,557 per LYS for bupropion 
(vs no treatment). However, despite being more expensive than 
bupropion, the investigators found varenicline to be the most 
cost-effective option due to increased efficacy. The LYS data 
for genetically tailored therapy and NRT were not given, but 
they were considered to be dominated by other therapies. The 
sensitivity analysis demonstrated that the ICERs for vareni-
cline ranged from US$1,091 to US$5,381 per LYS compared 
to the next most effective admissible therapy (bupropion in 
all but one scenario).
Patient-focused outcomes 
and safety
There are many barriers to successful cessation of smoking 
including concern over weight gain, the fear of relapse, and 
general lack of support.19 However, the greatest barriers are 
undoubtedly symptoms of withdrawal as the smoker struggles ClinicoEconomics and Outcomes Research 2009:1 32
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to overcome the physical addiction to nicotine and the 
psychological dependence on the act of smoking itself. One 
of the potential benefits to varenicline use as demonstrated in 
the trial by Tonstad et al17 is that the drug appears to possess 
the potential to help patients maintain abstinence with con-
tinued use. However, due to its novel mechanism of action, 
varenicline users note that even during active treatment the 
pleasure they receive from using tobacco is diminished, and 
cravings are tempered.
Subjects in the study by Nides et al had cravings assessed 
via the Minnesota Nicotine Withdrawal Scale (MNWS) and 
the Brief Questionnaire of Smoking Urges (QSU-Brief). 
Investigators found that cravings were significantly dimin-
ished in varenicline users compared to placebo users at 
each week of analysis.13 In addition, when asked about the 
satisfaction they received from smoking, and the enjoyment 
that smoking provided in terms of respiratory tract sensation, 
subjects reported a statistically significant decrease (again vs 
placebo) during the lead in week when they were still using 
tobacco. Comparable results were reported by Aubin et al14 
Subjects in that study reported diminished cravings versus 
NRT, as well as fewer negative changes in affect and rest-
lessness (P  0.001 for all). Another rating scale, the Modi-
fied Cigarette Evaluation Questionnaire (mCEQ) produced 
results demonstrating decreased satisfaction when smoking 
(P  0.001), decreased psychological reward (P = 0.001), 
less enjoyment of the sensation provided by smoking in the 
respiratory tract (P  0.001), and significant reduction in 
craving (P  0.001). However, there was no difference in 
the aversion subscale. Data from the studies by Gonzalez 
and Jorenby were similar, MNWS data showing superior-
ity with varenicline vs placebo for urge to smoke, negative 
affect, and total craving (P = 0.001 to P  0.001), while 
mCEQ data were significantly better compared to placebo 
for smoking satisfaction, psychological reward, enjoyment 
of respiratory tract sensation and craving reduction (P = 0.04 
to p  0.001).15,16 QSU-Brief data demonstrated a decrease 
in total craving score (P  0.001).15
Most adverse effects observed in clinical trials have been 
mild and transient. A study of 337 subjects was conducted to 
evaluate the long-term safety of varenicline use.32 Subjects 
were followed for a total of 53 weeks, and varenicline 1 mg 
twice daily or placebo were given for the first 52 (randomiza-
tion was completed at a ratio of 2:1) The overall rate of reported 
side-effects over the course of the trial for varenicline was 
96.4%, and for placebo was 82.5%. Typically, side-effects 
were noted within the first 4 weeks of the trial, and were mild 
to moderate. The most common complaint with varenicline 
treatment was nausea (40.2%). Varenicline is known to have 
mild affinity for serotonin receptors which may contribute to 
the notable rate at which this side effect occurs.33 Nineteen of 
the subjects that discontinued varenicline prematurely due to 
side-effects (28.3% overall in the varenicline group compared 
with 10.3% in the placebo group) did so because of nausea. 
Abnormal dreams were experienced by 22.7% of varenicline 
users, and insomnia was a complaint for 19.1%. In clinical 
trials, insomnia is typically more common in users of bupro-
pion compared to varenicline.13,15,16 Of note, both nausea and 
insomnia are often attributable to nicotine withdrawal.32 Eleva-
tions in liver enzymes were noted in two varenicline-treated 
subjects necessitating discontinuation. Hypokalemia led to 
discontinuation in a third. Only one serious adverse event, a 
case of bilateral subcapsular cataracts 125 days into the study, 
was attributed to varenicline by the investigators.
The rate of study withdrawal secondary to adverse events 
in the trials previously summarized ranged from 1.7% to 
11.2% with regular varenicline dosing.13–17 In comparison, 
withdrawal rates with placebo were 1.3% to 9%. Bupropion 
SR users withdrew at rates of 12.6% to 15.9% (consistently 
higher than varenicline in all studies where the two medica-
tions were compared), and nicotine users withdrew at a rate 
of 4.3% in the study by Aubin et al.14 The most frequent 
adverse effects were constant among the different studies. 
As expected, nausea occurred with the highest prevalence 
(28.1% to 52%). Additionally, insomnia (14% to 35.2%), 
headache (12.8% to 24%), and abnormal dreams (10.3% to 
15.2%) were frequent complaints.13–17
In the fourth quarter of 2007, the FDA received nearly 1,000 
reports of adverse events that occurred in varenicline users. 
Seventy-eight patients for whom the drug was prescribed died 
potentially due to effects related to varenicline.34 Concerns 
about the safety of the drug were raised by the Institute for Safe 
Medication Practices (a consumer “watchdog” organization).35 
An early alert was initially put forth in November 2007. Shortly 
thereafter, a public health advisory was sent out by the FDA 
warning practitioners about concerns over neuropsychiatric 
symptoms in patients using varenicline.8 Symptoms that had 
been observed included behavioral changes, mood disorders, 
generalized agitation, and in some cases, suicidal ideation. 
At the time, the FDA recommended that prescribers obtain a 
thorough psychiatric history and advised that monitoring for 
changes be completed during treatment.36 The labeling for 
varenicline now includes a warning that the drug has been asso-
ciated with changes in behavior and suicide. (Bupropion labeling 
also includes a black box warning noting an increase in suicide 
risk for patients using drugs in the antidepressant class).ClinicoEconomics and Outcomes Research 2009:1 33
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Clinical trial results did not raise concerns about 
neuropsychiatric side-effects, though most did not allow 
patients with a history of depression to participate.37 One 
patient in the maintenance therapy trial conducted by 
Tonstad et al did commit suicide 27 days after completion 
of the double-blind portion of the study. (The patient had 
a history of depression that had not been disclosed to the 
investigators).17 Possibly, the size of the studies that were 
completed prior to varenicline approval were not large 
enough to detect a trend in neuropsychiatric adverse events.38 
A causal link between varenicline and suicidal behavior has 
not been proven, and two out of three patients included in 
the report from the Institute of Safe Medication Practices 
were taking other medications that were not ruled out as 
causes or contributors to symptoms (benzodiazepines most 
often).34 In addition, relative risk must be considered as there 
were over four million users of varenicline in 2007. It has 
been hypothesized that some of the psychiatric effects may 
be related to tobacco withdrawal instead of drug therapy.39 
However, these adverse events have been noted in patients 
using varenicline who had not yet ceased smoking, thus ruling 
out the possibility that withdrawal was solely to blame.36 In a 
study that included both subjects with and without a history 
of depression, rates of new or worsening symptoms were not 
increased in the former group.37 Depression symptom scores 
were noted to be similar in both groups at 3 weeks. However, 
as there were no control groups (with or without a history 
of depression) that were not exposed to medication, the 
investigators were not able to discern if an increase in or new 
onset of depression was attributable primarily to varenicline, 
nicotine withdrawal, or some other reason.37 Since it is not 
possible to know the underlying etiology of neuropsychiatric 
disturbances in patients who use varenicline using existing 
data, it is prudent to engage in increased monitoring in all 
patients who are actively attempting smoking cessation.39
Conclusion
Various models of analysis have demonstrated that varenicline 
consistently exceeds existing threshold criteria for cost-
effectiveness. Though in terms of treatment costs alone 
varenicline is typically the most costly option among the 
FDA-approved medications, its superiority in achieving 
long-term abstinence results in substantial savings because of 
subsequent avoidance of morbidity and mortality that would 
otherwise result in increased consumption of healthcare 
resources. Additionally, varenicline becomes cost-effective 
within a comparatively short period of time which should 
allay some of the concerns expressed by payers and employers 
that they will be unlikely to recoup their investment prior to 
the time an individual changes plans or employment. Patient 
acceptance of varenicline is high, and the novel partial agonist 
has been shown to decrease cravings and withdrawal symp-
toms, and to blunt the positive reinforcement associated with 
smoking. The side-effect profile of varenicline is generally 
mild, transient nausea being the most observed adverse event. 
Cases of major depression and suicidal ideation have been 
reported with varenicline use, and although causality has not 
been definitively proven, caution is warranted if the drug is 
to be used in an individual with a history of neuropsychiatric 
disturbance, and patients should be warned about the poten-
tial for new onset of symptoms. Overall, given the efficacy, 
cost-effectiveness, and safety profile of varenicline, it should 
be considered among the best choices for smoking cessation 
therapy. However, as with any therapy, individual patient 
characteristics should be assessed in order to make the most 
appropriate medication choice.
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